Edelris s.a.s., a medicinal chemistry company focused on applying its Edelris Discovery Engine (EDEN) technology toward the generation of innovative small molecule leads, announced the signing of a research collaboration agreement with Pfizer Inc.
Under the terms of the agreement, Edelris will apply its large, diverse and tractable small molecule library platform (Keymical Space) as well as its organic, high-throughput and medicinal chemistry expertise to collaborate with Pfizer towards the identification of novel leads against Pfizer-selected targets. The financial terms of the agreement were not disclosed.
“Edelris has spent the past decade charting untapped areas of biorelevant chemical space, and has developed efficient ways to mine this resource,” said Jean-Yves Ortholand, chief executive officer of Edelris. “We are excited to challenge this space containing very fresh and innovative chemical matter with some important and potentially therapeutically relevant targets selected by leaders in the pharmaceutical industry such as Pfizer.”
Tony Wood, senior vice president and head of medicinal sciences at Pfizer said, “We look forward to working with Edelris to explore the use of their natural product-inspired technology to potentially access novel chemical leads.”
(Source: Edelris s.a.s.)
Filed Under: Drug Discovery
